Campbell Bunce

Campbell Bunce, PhD MBA, has a wealth of experience in the biopharmaceutical industry. Campbell currently serves as the Chief Scientific Officer at Abzena, where they lead the development of bioconjugate and biologics treatments. Prior to this role, they were the Senior Vice President of Scientific Operations at the same company, where they focused on customer growth and successful project delivery.

Before joining Abzena, Dr. Bunce worked as the General Manager of Immunology Products at Oxford Immunotec and as the R&D Director at Immune Targeting Systems. Campbell also ran their own consulting company, Tuig R&D Services Limited, where they provided services to the biopharma sector, specializing in immunology and the development of novel products.

Their previous roles include Development Programmes Director at Piramed, where their work contributed to the acquisition of the company by Roche, and Project Director at Celtic Pharma Development Services. Dr. Bunce also served as a Projects Leader/Manager at Xenova Limited and as a Senior Project Scientist at Cantab Pharmaceuticals. In these roles, they focused on the development and management of drug development programs, with a particular emphasis on cancer and inflammation.

Campbell Bunce holds an Executive MBA in Business Administration and Management from Cambridge Judge Business School, which was obtained from 2019 to 2021. Campbell also obtained a PhD in Immunology from The University of Manchester, completing their studies from 1992 to 1996. Additionally, they attended the University of Glasgow from 1988 to 1992, although the specific degree and field of study are undisclosed.